Key Insights Significantly high institutional ownership implies CVS Health's stock price is sensitive to their ...

CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.

CVS Health (CVS) and UnitedHealth Group (UNH), two of the largest players in the healthcare sector, recently reported their Q2 earnings, showing contrasting performances. While CVS delivered strong ...

Over the last quarter, CVS Health insiders have spent a meaningful amount on shares. Specifically, Independent Director Guy Sansone bought US$100k worth of shares in that time, and we didn't record ...

Over the past six months, CVS Health has been a great trade, beating the S&P 500 by 13.8%. Its stock price has climbed to $65.46, representing a healthy 19% increase. This was partly thanks to its ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $78.33, with a high estimate of $82.00 and a low estimate of $67.00. Marking an increase of 2 ...

CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive ...

Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing ...

While CVS Health has outperformed the broader market this year, Wall Street analysts are strongly bullish about its future potential.

CVS faces pressures from rising medical costs, but promising guidance, stable finances, and low valuations suggest strong potential for returns. Read why I rate the stock a buy.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...